Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Safety, PK/PD and Immunogenicity of SS109 in Hemophilia Patients With Blood Coagulation Factor Ⅷ or Ⅸ Inhibitors After Single Administration, Open Label, Dose Escalation, and Multicenter Phase I Clinical Trial

NCT05651061 is registered in ClinicalTrials.gov with Hangzhou Gensciences Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05651061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05651061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Safety, PK/PD and Immunogenicity of SS109 in Hemophilia Patients With Blood Coagulation Factor Ⅷ or Ⅸ Inhibitors After Single Administration, Open Label, Dose Escalation, and Multicenter Phase I Clinical Trial
Lead sponsor
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
December 14, 2022
Completion date
August 15, 2023
Enrollment
27 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

factor vii deficiency, hemophilia a with inhibitor, hemophilia b with inhibitor